Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS (LIVERHOPE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

...rolled in two trials in DE, ES, FR, IT, UK). The expected impact is to halt progression to acute-on-chronic liver failure, the main cause of death, to decrease complications of the disease, to reduce hospital readmissions, to improve cost-effectiveness of therapy. Our final aim is to improve patients quality-of-life and increase survival as patients‘ care is the core of LIVERHOPE. Within the proje ...
Voir le projet

 18

 TERMINÉ 

Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Segmental Artery Coil-Embolization’: A Randomized Controlled Multicentre Trial (PAPA-ARTIS)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients’ prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in ...
Voir le projet

 26

 TERMINÉ 

Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial (PROOF)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Ischemic stroke (IS), caused by occlusion of arteries that supply blood to the brain, remains a leading cause of mortality and morbidity in the world. Disruption of blood and oxygen supply to the brain leads to neuronal death in the ischemic core within minutes. The hypoperfused tissue surrounding the ischemic core, the penumbra, is at high risk for infarction over time but still salvageable. Neur ...
Voir le projet

 13

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet

 44

 TERMINÉ 

An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2021,

The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet

 43

 TERMINÉ 

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy (NoCanTher)

Date du début: 1 avr. 2016, Date de fin: 31 mars 2021,

During the last four years the Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by ...
Voir le projet

 13

 TERMINÉ 

A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours (Lumiblast)

Date du début: 1 oct. 2016, Date de fin: 31 mars 2021,

... photosensitive agents to become activated, killing the tumour cells from the inside. Lumiblast requires a concerted interdisciplinary action. The project coordinator (Berg’s group, Oslo University Hospital, OUS) is world renowned in PDT and photomedicine, while the team from the University of Athens (Georgios Vougioukalakis’ group, UoA) is up and coming with high expertise in synthetic chemistry. ...
Voir le projet

 6

 TERMINÉ 

Biomaterials and Additive Manufacturing: Osteochondral Scaffold innovation applied to osteoarthritis (BAMOS)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

Osteoarthritis (OA) is a degenerative joint disease, typified by a loss of quality of cartilage and changes in bone at the interface of a joint, resulting in pain, stiffness and reduced mobility. BAMOS project particularly addresses the challenges in OA treatment by providing novel cost effective osteochondral scaffold technology for early intervention of OA to delay or avoid the joint replacemen ...
Voir le projet

 4

 TERMINÉ 

EURopean Endeavour for Chimeric Antigen Receptor Therapies (EURE-CART)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing ...
Voir le projet

 11

 TERMINÉ 

Paediatric Clinical Research Infrastructure Network (PedCRIN)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

Children’s health is a major societal challenge for Europe and the world, requiring development of paediatric medicines and treatments strategies based on evidence derived from clinical trials demonstrating efficacy and safety in infants and children, rather than on uncritical extrapolation from adult data (over 50 % of the medicines used for children had not been tested in this specific age group ...
Voir le projet

 16

 TERMINÉ 

Boost Brittle Bones Before Birth (BOOSTB4)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal m ...
Voir le projet

 13

 TERMINÉ 

Understanding asthma phenotypes: going beyond the atopic/non-atopic paradigm (AsthmaPhenotypes)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Fifteen years ago it was widely believed that asthma was an allergic/atopic disease caused by allergen exposure in infancy; this produced atopic sensitization and continued exposure resulted in eosinophilic airways inflammation, bronchial hyper-responsiveness and reversible airflow obstruction. It is now clear that this model is at best incomplete. Less than one-half of asthma cases involve allerg ...
Voir le projet

 6

 TERMINÉ 

Children’s Liver Tumour European Research Network (ChiLTERN)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying ...
Voir le projet

 21

 TERMINÉ 

INtestinal Tissue ENgineering Solution (INTENS)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

...have an internationally pre-eminent, multi-disciplinary team, which possesses a combination of expertise from basic molecular biology, engineering, and surgery, combining knowledge from universities, hospitals and industry. Importantly we are one of the few groups in the world with experience, infrastructure, and track record to translate regenerative medicine solutions to patients, including true ...
Voir le projet

 9

 TERMINÉ 

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Voir le projet

 43

 TERMINÉ 

Comorbid Conditions of Attention deficit / hyperactivity disorder (CoCA)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Understanding mechanisms underlying comorbid disorders poses a challenge for developing precision medicine tools. Psychiatric disorders are highly comorbid, and are among the last areas of medicine, where classification is driven by phenomenology rather than pathophysiology. We will study comorbidity between the most frequent psychiatric conditions, ADHD, mood/anxiety, and substance use disorders, ...
Voir le projet

 17

 TERMINÉ 

Empowering Patients by Professional Stress Avoidance and Recovery Services (STARS)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

...our proposal addresses an advanced, eHealth based concept for tailored avoidance and/or reduction of healthcare related stress, beginning as early as in the preclinical phase, proceeding during their hospitalisation until the end of the aftercare period. I.a. it can be expected that, recovery time will be shortened, harmful side-effects of sedating drugs will be prevented and costs will be reduced ...
Voir le projet

 13

 TERMINÉ 

Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe.Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults. Despite hypothermia and neonatal inte ...
Voir le projet

 18

 TERMINÉ 

Arrhythmias monitoring and comprehensive care (RITMOCORE)

Date du début: 1 nov. 2016, Date de fin: 31 déc. 2020,

...ome monitoring of vital signs using wearables, Apps and available innovative devices; patient activation and increases the alignment of objectives among all involved stakeholders (providers, doctors, Hospital managers, patients).To achieve these goals RITMOCORE proposes to move from a conventional purchasing of devices to an innovative service provision able to complement the resources of the publ ...
Voir le projet

 9

 TERMINÉ 

Training European Network: Metabolic Dysfunctions associated with Pharmacological Treatment of Schizophrenia (TREATMENT)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

TREATMENT is a Marie Sklodowska Curie Innovative Training Network proposal directly addressing the need for high-level training and career paths in risk evaluation of drug induced metabolic dysfunctions, a relevant aspect, so far unexplored by traditional toxicology studies, but urgently needed to challenge current severe limitations of health care interventions in mental disorders. These patients ...
Voir le projet

 9

 TERMINÉ 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Date du début: 1 juin 2015, Date de fin: 30 nov. 2020,

...utes (state-of-the-art tools) and SME/Industry (certified tool analyses and logistics) which also collaborate with large US-based OAI and MOST cohorts. This group is engaged with end users in hospitals and patient advocacy groups actively involved in OA awareness, fundraising and research support. The consortium crosses barriers and enables inter-sectorial collaborations that bring together all th ...
Voir le projet

 25

 TERMINÉ 

Big data against childhood Obesity (BigO)

Date du début: 1 déc. 2016, Date de fin: 30 nov. 2020,

Childhood and adolescent obesity is a major global and European public health problem. Currently, public actions are detached from local needs, mostly including indiscriminate blanket policies and single-element strategies, limiting their efficacy and effectiveness. The need for community-targeted actions has long been obvious, but the lack of monitoring and evaluation framework and the methodolog ...
Voir le projet

 14

 TERMINÉ 

Training, Research and Raising of Public Awareness in Cell Biology and Pathology of Neuroglia (EU-GliaPhD)

Date du début: 1 déc. 2016, Date de fin: 30 nov. 2020,

The research in which the young scientists of the EU-GliaPhD consortium will be trained is centred on the role of neuron-glia interactions in brain function and pathology.Prompted by exciting discoveries of recent years, many academic research groups are currently focussing their research on the field of neuron-glia interactions for a better understanding of brain function. Also the private sector ...
Voir le projet

 13

 TERMINÉ 

Harnessing Targeted Nanotheranostics to Reprogram Activated Leukocytes in Inflammatory Bowel Disease (LeukoTheranostics)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,

"Inflammatory bowel diseases (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn’s disease (CD) and Ulcerative Colitis (UC) that can impact both the large and small bowel. IBD affects approximately 3.7 million Europeans and its peak onset is in persons of 15 to 30 years of age. IBD imposes a significant burden on Europe with over €3B in annual health ...
Voir le projet

 2

 TERMINÉ 

High Performance Soft-tissue Navigation (HiPerNav)

Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,

Primary liver cancer, which consists predominantly of hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third most common cause of cancer mortality. A successful surgical resection of HCC requires complete removal of the tumour while sparing as much healthy tissue as possible. Due to technical and clinical difficulties relatively low percentage of patients are eligi ...
Voir le projet

 10

 TERMINÉ 

Development of DIALIVE, a novel Liver Dialysis Device for the treatment of patients with Acute on Chronic Liver Failure (ACLF) (ALIVER)

Date du début: 1 janv. 2017, Date de fin: 30 sept. 2020,

...he ALIVER Consortium are positive. We plan to take the project through regulatory and ethics approval and perform two studies to define its safety and efficacy in ACLF patients in 18 European hospitals; define health economic benefits to the EU and define a reimbursement strategy. The results will be disseminated widely and results exploited to benefit patients, EU healthcare system, create new jo ...
Voir le projet

 12

 TERMINÉ 

Tribbles Research and Innovation Network (TRAIN)

Date du début: 1 sept. 2016, Date de fin: 31 août 2020,

This proposal was developed in the context of the medical need to tackle the clinical consequences of obesity-related diseases more holistically. Dysregulation of common molecular pathways that govern the physiological functioning of adipocytes, immune cells and prostate epithelium cells have been reported in immuno-metabolic disease (such as obesity) and several cancers. The individual projects ...
Voir le projet

 10

 TERMINÉ 

Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast can ...
Voir le projet

 13

 TERMINÉ 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Voir le projet

 29

 TERMINÉ 

Cancer: Activating Technology for Connected Health (CATCH)

Date du début: 1 sept. 2016, Date de fin: 31 août 2020,

Advances in cancer diagnosis and treatment have been groundbreaking, and we are now considering some cancers as chronic disease rather than fatal illness. This moves the point of focus in the fight against cancer from sustaining life towards maximizing functional capacity and quality of life (QOL). A critical element in this shift has been the rise of active rehabilitation in the management of can ...
Voir le projet

 6

 TERMINÉ 

iABC Programme (IABC PROGRAMME)

Date du début: 1 août 2015, Date de fin: 31 juil. 2020,

...d health-related quality of life. Chronic infection with Pa affects 12–27% of adults with BE and is associated with an increased exacerbation frequency, an accelerated decline in lung function, hospital admissions and increased mortality. There is a direct relationship between bacterial load, airway inflammation and risk of exacerbation supporting the use of long-term administration of inhaled ant ...
Voir le projet

 21

 TERMINÉ 

PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS)

Date du début: 1 juin 2015, Date de fin: 31 mai 2020,

Every year, 1.3 million Europeans have a stroke and one million ultimately die of stroke. One third of stroke patients remain dependent on the help of others. The annual costs for stroke care in Europe are estimated at € 64.1 billion. Stroke incidence increases almost exponentially with age, and the personal, societal, and economic burden of stroke is therefore largely driven by its frequent occur ...
Voir le projet

 20

 TERMINÉ 

Mechanisms of Evasive Resistance in Cancer (MERiC)

Date du début: 1 mai 2014, Date de fin: 30 avr. 2020,

Cancer is a major health problem due to the failure of current therapies to effectively eradicate the disease. Alternative signaling pathways compensate for a therapeutically targeted pathway, a process referred to as 'evasive resistance'. The identities of the alternative signaling pathways and functional interconnections that underlie evasive resistance remain widely unknown. We propose to integ ...
Voir le projet

 3

 TERMINÉ 

Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time (MDS-RIGHT)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

Myelodysplastic syndromes (MDS) are chronic bone marrow malignancies of the elderly, complicated by severe anaemia. MDS significantly affects quality-adjusted survival and it imposes an increasing financial burden on patients and healthcare (HC) systems. The burden of disease is expected to worsen in the future, given the aging EU population and newly identified MDS cases among those diagnosed wit ...
Voir le projet

 16

 TERMINÉ 

Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia (AML-VACCiN)

Date du début: 1 janv. 2016, Date de fin: 31 mars 2020,

Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a deadly rare disease that affects both children and adults. Approximately 45% of younger AML patients who are treated will be cured, and in older patients (>60 years of age), 85% will relapse and die within 2 years.Immunotherapy has great potential for treating M ...
Voir le projet

 12

 TERMINÉ 

Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,

Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet

 44

 TERMINÉ 

Zorg verbindt

Date du début: 1 mars 2016, Date de fin: 28 févr. 2020,

...nt against arthritis•Remote monitoring of blood pressure self-measurement•Dental care for the elderly for care takers and caring relatives•Benchmark infection-prevention in surgery•NL/D hospital cooperation Big helps small•Remote depression-treatment •Solution doctor shortage•Care in rural border regions (Cara)•Hospitals learn from each other Moreover, matching conversations, potential field labs ...
Voir le projet

 39

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Carbapenem Resistance (COMBACTE-CARE)

Date du début: 1 mars 2015, Date de fin: 28 févr. 2020,

...ions for the development of novel antibiotic agents for MDR GNB; will (2) provide new knowledge on the clinical management and outcomes of patients (neonates/children and adults) with serious hospitalised infections and will validate this knowledge for clinical outcomes for patients in areas of emerging and endemic antibiotic resistance; will (3) support the sustainability of ND4BB supported inves ...
Voir le projet

 23

 TERMINÉ 

Accelerating HIV Cure in Europe (EU4HIVCURE)

Date du début: 1 févr. 2016, Date de fin: 31 janv. 2020,

.../AIDS CURE. To accelerate the State of the Art in HIV CURE research in Europe, our EU4HIVCURE consortium brings together an intersectoral and interdisciplinary collaboration between 3 Universities, 3 Hospitals, 1 International Research Organisation from 4 European countries and 1 University from Canada. Our aim is to dissect the intricate mechanisms controlling HIV-1 latency and identify new drugg ...
Voir le projet

 6

 TERMINÉ 

European Gram Negative Antibacterial Engine (ENABLE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Voir le projet

 42